Evidence map›Paper›PMID 40663653›Full record

ArticleBriefings in bioinformatics2025

Kinase-inhibitor binding affinity prediction with pretrained graph encoder and language model.

Xudong Guo, Zixu Ran, Fuyi Li

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xudong GuoCollege of Information Engineering, Northwest A&F University, Yangling, 712100, China.
Zixu RanCollege of Information Engineering, Northwest A&F University, Yangling, 712100, China.
Fuyi LiCollege of Information Engineering, Northwest A&F University, Yangling, 712100, China.

Funding

National Key Research and Development Program of China 2022YFF1000100National Natural Science Foundation of China 62202388Qin Chuangyuan Innovation and Entrepreneurship Talent Project QCYRCXM-2022-230
6 · The paper itself

Abstract

Accurately predicting inhibitor-kinase binding affinity is crucial in drug discovery and medical applications, especially in the treatment of diseases such as cancer. Existing methods for predicting inhibitor-kinase affinity still face challenges, including insufficient data expression, limited feature extraction, and low performance. Despite the progress made through artificial intelligence methods, particularly deep learning technology, many current methods fail to capture the intricate interactions between kinases and inhibitors. Therefore, it is necessary to develop more advanced methods to solve the existing problems in inhibitor-kinase binding prediction. This study proposed Kinhibit, a novel framework for inhibitor-kinase binding affinity prediction. Kinhibit integrates self-supervised graph contrastive learning with multiview molecular graph representation and structure-informed protein language model (ESM-S) to extract features effectively. Kinhibit also employed a feature fusion approach to optimize the fusion of inhibitor and kinase features. Experimental results demonstrate the superiority of this method, achieving an accuracy of 92.6% in inhibitor prediction tasks of three mitogen-activated protein kinase (MAPK) signalling pathway kinases: Raf protein kinase (RAF), Mitogen-activated protein kinase kinase (MEK), and Extracellular Signal-Regulated Kinase (ERK). Furthermore, the framework achieves an impressive accuracy of 92.9% on the MAPK-All dataset. This study provides promising and effective tools for drug screening and biological sciences.

Indexed as

Protein Kinase InhibitorsComputational BiologyDeep LearningDrug DiscoveryHumansProtein BindingProtein Kinase Inhibitorsbinding affinitycontrastive learninggraph neural networkinhibitorkinase

Identifiers

PMID40663653
PMCPMC12262122

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.